Anticancer activity of cissampelos pareira against dalton’s lymphoma ascites bearing mice

B. Samuel Thavamani, Molly Mathew¹, S. P. Dhanabal²

Department of Pharmacognosy, PSG College of Pharmacy, Peelamedu, Coimbatore, ¹Malik Deenar College of Pharmacy, Kasargod, Kerala, ²Department of Phytopharmacy and Phytomedicine, JSS College of Pharmacy (JSS University, Mysore), Ooty, Tamil Nadu, India

Submitted: 03-11-2013 Revised: 05-01-2014 Published: 24-07-2014

ABSTRACT

Background: Cissampelos pareira (Menispermaceae) is used in folk Indian system of alternative medicine, for its analgesic, antipyretic, diuretic, antilithic, and emmenagogue properties. Objective: To evaluate Cissampelos pareira (C. pareira) for in vitro cytotoxicity and in vivo antitumor activity against Dalton’s Lymphoma Ascites (DLA) cells in Swiss mice. Materials and Methods: Cissampelos pareira was successively extracted using different solvents. In vitro cytotoxicity was assessed by the MTT assay. An in vivo study was carried out in methanol extract. Twenty-four hours after intraperitoneal inoculation of the DLA cells in mice, the methanol extract of C. pariera (MECP) was administered at 200 and 400 mg/kg body weight for 14 consecutive days. On day 14, six mice were sacrificed and the rest were kept alive for assessment of increase in life-span. The antitumor effect was assessed by evaluating the packed cell volume, viable tumor cell count, increase in body weight, and increase in life-span. The hematological and serum biochemical parameters and anti-oxidant properties were assessed by estimating the superoxide dismutase (SOD), catalase (CAT), and lipid peroxidation. Results: Methanol Extract of Cissampelos pariera (MECP) showed a potent cytotoxic activity, with an IC₅₀ value of 95.5 μg/ml and a significant (P < 0.001) decrease in packed cell volume, viable cell count, and an increased lifespan (54 and 72%). The hematological and serum biochemical profiles were restored to normal levels in MECP-treated mice. The MECP-treated group significantly (P < 0.001) decreased SOD, lipid peroxidation, and CAT to normal. Conclusion: This study demonstrated that C. pariera exhibited significant in vitro and in vivo anti-tumor activities and that it was reasonably imputable to its increasing endogenous mechanism of antioxidant property.

Key words: Antioxidant, antitumor, Cissampelos pariera, cytotoxicity, Menispermaceae

INTRODUCTION

Cancer is a major health issue, despite the advancement in the healthcare sector. The present day research is aimed at identifying synthetic and natural molecules to be used in the prevention or treatment of cancer. Chemotherapy is considered as the most effective method, among many other methods prevalent, to treat cancer. However, chemotherapeutic agents affect the host cells, especially the bone marrow, epithelial tissues, reticuloendothelial system, and gonads.¹ There are several chemotherapeutic agents that produce serious chronic or delayed toxicities that may be irreversible, particularly in the heart, lungs, and kidneys.² Therefore, a novel approach to reduce unwanted toxicity is to employ newer natural products that may act with different and distinct mechanism(s) and/or reduce the side effects. Hence, at present, natural products have been contemplated to be of exceptional value in the development of effective anticancer drugs, with minimum host cell toxicity, possessing good antioxidant potential.³

Cissampelos pariera Linn. (Menispermaceae) is a climbing shrub that grows in the tropical and subtropical regions of India. C. pareira is also called as the Midwives’s herb, as it is used in the treatment of the female reproductive system. It is used as an astringent, antispasmodic, analgesic, antipyretic, diuretic, antilithic, and emmenagogue.⁴ The plant is reported to have cardioprotective,⁵ hepatoprotective,⁶ antioxidant and immunomodulatory,⁷ antifertility,⁸ antiarthritic,⁹ and anti-inflammatory activities.¹⁰ The plant is reported to have phytoconstituents like cissampeloflavone,¹¹ cissamparine,¹² pareirubrines A and B,¹³ hayatinin,¹⁴ and protoberberine alkaloids.¹⁵ No pharmacological investigation in the perspective of...
antitumor activity has yet been reported on *C. pariera*. Therefore, the present study evaluates the *in vitro* and *in vivo* anticancer properties of *C. pariera*.

**MATERIALS AND METHODS**

**Collection and extraction of plant materials**
The whole plant was collected in October 2011, from Kalakkad, Tirunelveli District, in South India. The specimen was identified by Prof. V. Chelladurai, Research Officer - Botany, C.C.R.A.S. Govt. of India (Retired). A voucher specimen was prepared in our research laboratory and maintained with voucher no. PSGCP/DPC/02, for further reference. Immediately after collection, the whole plant was washed thoroughly with water and shade-dried at room temperature. The shade dried plant was then pulverized to form a coarse powder and used for extraction. The crude drug was successively extracted in a Soxhlet apparatus, using hexane, petroleum ether, chloroform, methanol, ethyl acetate, and water. The solvents were removed by distillation on a water bath at atmospheric pressure. The final traces of solvents were removed with the help of a rotary evaporator under reduced pressure and the residual solvents were found to be within the limits of the International Conference on Harmonization (ICH) guidelines 2012. All the extracts were subjected to *in vitro* anti-proliferative activity against the MCF-7 cancer cell line. The methanol extract of *C. pariera* (MECP) was used for *in vivo* antitumor activities.

**Estimation of the total alkaloid, phenolic, and flavonoid content**
The total amount of alkaloids present in the crude extract was assayed as per the protocol reported earlier. Total phenolic and flavonoid contents were determined in the MECP extract using the Folin-Ciocalteu reagent and Dowd method, respectively.

**In vitro cytotoxic studies**
The human breast cancer cell line (MCF-7) was obtained from the National Center for Cell Science (NCCS), Pune, and grown in the Eagles Minimum Essential Medium containing 10% fetal bovine serum (FBS). All the cells were maintained at 37°C, 5% CO₂, 95% O₂ air, and 100% relative humidity. The maintenance cultures were passaged weekly and the culture medium was changed twice a week.

**Cell treatment procedure**
The monolayered cells were detached with trypsin-ethylene diamine tetra acetic acid (EDTA) to make a single cell suspension. The viable cells were counted using a hemocytometer and diluted with a medium with 5% FBS, to give a final density of 1 x 10⁵ cells/ml. The cell suspension (100 µL per well) was seeded into 96-well plates at a plating density of 10,000 cells/well, and incubated at 37°C, 5% CO₂, 95% O₂, and 100% relative humidity. After 24 hours the cells were treated with serial concentrations of the extracts. They were initially dissolved in dimethylsulfoxide (DMSO) and further diluted in a serum-free medium, to produce five concentrations. Each concentration (100 µl per well) was added to the plates, to obtain final concentrations of 250, 125, 62.5, 31.25, and 15.62 µg/ml. The final volume in each well was 200 µl and the plates were incubated at 37°C, 5% CO₂, 95% air, and 100% relative humidity for 48 hours. The medium without samples served as the control. Triplicates were maintained for all concentrations. After 48 hours of incubation, 15 µl of MTT (5 mg/ml) in phosphate-buffered saline (PBS) was added to each well and incubated at 37°C for four hours. The medium with MTT was then flicked off and the formed formazan crystals were solubilized in 100 µl of DMSO and then the absorbance was measured at 570 nm using a microplate reader. The percent cell inhibition was determined using the following formula.

\[
\text{Percent cell inhibition} = 100 - \frac{\text{Absorbance (sample)}}{\text{Absorbance (control)}} \times 100
\]

The non-linear regression graph was plotted between percent cell inhibition and Log₁₀ concentration, and IC₅₀ was determined using the GraphPad Prism 6 software.

**Acute toxicity**
The acute toxicity in male Swiss albino mice was studied as per the Organization for Economic Cooperation and Development (OECD) guideline 425. The LD₅₀ value of MECP was determined using the method of maximum likelihood.

**Induction of cancer using Dalton’s lymphoma ascites cells**
Dalton’s Lymphoma ascites (DLA) cells were obtained under the courtesy of the Amala Cancer Research Center, Thrissur, Kerala, India. The cells were maintained *in vivo* in Swiss albino mice by intraperitoneal administration. When transforming the tumor cells to the grouped animals, the DLA cells were aspirated from the peritoneal cavity of the mice by using saline. The cells were counted and further diluted, so that the total cells would be 1 x 10⁶/mouse. This dilution was given intraperitoneally.

**Animals**
Male and female adult Swiss Albino mice, about 8 weeks old, with an average body weight of 23 ± 2 g were procured from the KM College of Pharmacy, Madurai,
Tamil Nadu. They were housed in microloan boxes, in a controlled environment, with a temperature of 25 ± 2°C and a 12 hour dark/light cycle, with a standard laboratory diet, and water ad libitum. The study was conducted after obtaining clearance from the Institutional Animal Ethical Committee (Protocol. No. IAEC/KMCP/92/2013). The mice were segregated based on their gender and acclimatized for 15 days before commencement of the experiment.

Treatment protocol
The animals were divided into five groups (n = 12). All the groups, except the first group, received 0.1 ml cell suspension of the DLA tumor cell line (1 × 10^6 cells/mouse, i.p). This was considered as day '0'. The first group served as the normal saline control, which received normal saline of 5 mL/kg body weight, orally (p.o). The second group served as the DLA tumor cell line control. The third group received the standard drug 5-fluorouracil (20 mg/kg body weight, i.p.) for nine consecutive days. After 24 hours of tumor inoculation, the fourth and fifth groups received MECP at doses of 200 and 400 mg/kg body weight, p.o. On day 15, blood was withdrawn by sterile syringe and diluted with 0.8% sterile Phosphate Buffer Solution and 0.1% tryphan blue (0.1 mg/ml) and the total number of the living cells was counted using a hemocytometer. The cell count was calculated by the formula:

\[
\text{Cell Count} = \frac{(\text{No. of cells in dilution})}{(\text{Area} \times \text{thickness of liquid film})}.
\]

Hematological parameters
Various hematological parameters including white blood cell (WBC) count, red blood cell (RBC) count, platelet count, hemoglobin, and packed cell volume, were determined.

Body weight
All the mice were weighed from the beginning to the fifteenth day of the study. An average increase in body weight on the fifteenth day was determined.

Percentage increase in lifespan
Percentage increase in lifespan (ILS) was calculated by the formula:

\[
\% \text{ ILS} = \frac{(\text{Lifespan of treated group}) - (\text{Lifespan of control group})}{\text{Lifespan of control group}} \times 100.
\]

Serum enzyme and lipid profile
The serum was analyzed for aspartate amino transferase (AST), alanine amino transferase (ALT), alkaline phosphatase (ALP), total cholesterol (TC), and triglycerides (TG). All biochemical investigations were done by using COBAS MIRA PLUS-S autoanalyzer from Roche, Switzerland. The hematological tests were carried out in COBAS MICROS OT 18 from Roche.

Estimation of Lipid peroxidation, Superoxide dismutase, Catalase
The thiobarbituric acid reactive substances (TBARS) in the cell lysate tissues were measured as per the method reported earlier.[21] The TBARS content was expressed in micromole/milligram (μmole/mg) of protein. The SOD activity in cell lysate was determined as per the method followed earlier.[22] Enzyme activity was expressed as 1 Unit = 50% inhibition/minute/milligram of protein. The CAT activity in cell lysate was assayed as per the method reported earlier.[23] CAT was expressed in terms of micromoles of hydrogen peroxide decomposed/minute/milligram of protein.

Statistical analysis
The values are represented as mean ± SD. The experimental data were assessed by the One-way Analysis of Variance (ANOVA) method followed by Tukey’s multiple comparison. The results were considered to be statistically significant when the P < 0.05.

RESULTS
Acute toxicity
The MECP did not show any toxic symptoms in animals over a period of 24 hours. The oral extract was non-lethal even at the single dose of 2000 mg/kg.

Secondary metabolites
Estimation of the secondary metabolites showed a significant content of total alkaloid (135.4 mg/100 g), total phenolic (39.5 GAE mg/g), and total flavanoid (4.47 RE mg/g) in MECP [Table 1].

In vitro anti-proliferative study
The MECP exhibited significant (P < 0.001) anti-proliferative activity against the breast cancer cell line MCF-7, with a mean IC_{50} value of 95.5 ± 4.9 μg/ml.
The IC<sub>50</sub> values of hexane, petroleum ether, chloroform, ethyl acetate, and aqueous extract were found to be 255 ± 17.88, 221.5 ± 16.68, 147 ± 7.9, 213.5 ± 8.4, and 224 ± 14.15 μg/ml, respectively [Figure 1].

**Effect on tumor growth**

The average lifespan of animals in the DLA tumor control group was found to be 48% [Table 2]. The average lifespan of animals treated with MECP at the doses of 200 and 400 mg/kg body weight was found to be 54 and 72%, respectively, whereas the average lifespan of the 5-FU treated group was found to be 92%. An increase in packed cell volume was observed in the DLA control mice when compared with the extract-treated group. The MECP-treated groups showed a significant (P < 0.001) reduction in packed cell volume. Similarly, the MECP-treated group exhibited a significant (P < 0.001) decrease in the viable cell count at a dose of 400 mg/kg when compared with the MECP-treated group (P < 0.01) at the dose of 200 mg/kg. Moreover, the antitumor nature of MECP at doses of 200 and 400 mg/kg was also evident by the significant (P < 0.001) reduction in percent increase in body weight of animals treated with MECP at doses of 200 and 400 mg/kg body weight, as compared to DLA tumor-bearing mice. All these results indicated that MECP had significant (P < 0.001) activity to inhibit tumor growth induced by the DLA cell line.

**Effect on hematological parameters**

The hematological parameters were significantly (P < 0.001) altered after 14 days of treatment when compared with the DLA control group. The total WBC count had increased in the DLA control cell whereas, the RBC count, hemoglobin, and platelets decreased in the DLA control cell. After treating for 14 days with MECP, at doses of 200 and 400 mg/kg, the body weight and hematological parameters had normalized, close to the normal group. The WBC significantly (P < 0.001) decreased in both the MECP-treated groups, and the RBC significantly (P < 0.01) increased in both the MECP-treated groups. Similarly, hemoglobin significantly (P < 0.001) increased in both the MECP-treated groups. Platelets significantly (P < 0.01) increased in both the MECP-treated groups. All these results suggest the antitumor nature of MECP at a dose of 200 and 400 mg/kg body weight. However, the reference drug 5-FU at the dose of 20 mg/kg body weight produced significant (P < 0.001) results in all these parameters [Table 3].

**Effect on biochemical parameters**

Biochemical parameters like aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), triglycerides (TGL), and serum cholesterol in the DAC control group were significantly (P < 0.001) elevated as compared to the normal saline group [Table 4].

---

**Table 1: Estimation of total alkaloid, phenolic, and flavanoid content of the extracts**

| Name of the extract     | Total alkaloid (mg/100 g) | Total phenolics GAE mg/g | Total flavanoids RE mg/g |
|-------------------------|---------------------------|--------------------------|--------------------------|
| Hexane extract          | 42.7                      | 36.4                     | 1.54                     |
| Petroleum ether extract | 53.5                      | 34.5                     | 1.74                     |
| Chloroform extract      | 155.3                     | 22.5                     | 3.72                     |
| Ethyl acetate extract   | 60.5                      | 29.4                     | 3.47                     |
| Methanol extract        | 135.4                     | 39.5                     | 4.47                     |
| Aqueous extract         | 33.8                      | 20.1                     | 1.24                     |

GAE: Gallic acid equivalent; RE: Rutin equivalent (at column width)

**Table 2: Effect of MECP on body weight, packed cell volume, viable cell count, and percent increased lifespan of tumor-induced mice**

| Groups                        | Increase in body weight (g) | Packed cell volume (ml) | Viable cell count (cells x10<sup>6</sup>/mL) | Percent ILS Lifespan |
|-------------------------------|-----------------------------|-------------------------|-------------------------------------------|---------------------|
| Normal saline (5 mL/kg)       | 2.32±0.51                   | -                       | -                                         | >30 days            |
| DLA control (1×10<sup>6</sup> cells/mouse) | 7.72±1.13<sup>***</sup> | 32.27±0.87              | 2.69±0.26                                 | 48%                 |
| DLA+5F uracil (20 mg/kg)      | 3.19±0.36<sup>***</sup>     | 18.56±0.62<sup>**</sup> | 1.46±0.21<sup>***</sup>                   | 92%                 |
| DLA+MECP (200 mg/kg)          | 4.13±0.38<sup>**</sup>      | 22.70±0.95<sup>**</sup> | 2.03±0.33<sup>***</sup>                   | 54%                 |
| DLA+MECP (400 mg/kg)          | 4.33±0.33<sup>**</sup>      | 21.58±0.50             | 1.71±0.28<sup>**</sup>                   | 72%                 |

Values are means±SEM (n=12). *DLA control group versus normal saline group, **All treated groups versus DLA control group, ***P<0.001. Data were assessed by the one-way ANOVA method followed by Tukey’s multiple comparison.
Treatment with MECP at doses of 200 and 400 mg/kg body weight significantly \((P < 0.001)\) reduced AST, ALT, ALP, and serum cholesterol to the normal values. The treatment with standard 5-FU also gave similar results.

**Effect on superoxide dismutase, catalase, and lipid peroxidation**

Superoxide dismutase and catalase activities were reduced significantly \((P < 0.001)\) in the DLA control groups compared to that of the normal group. Treatment of both the MECP group significantly \((P < 0.001)\) restored the SOD level to the normal value, when compared with the DLA control group. Similarly, administration of MECP at 200 and 400 mg/kg significantly \((P < 0.001)\) recovered the CAT level to the normal value when compared with the DLA control group [Table 5].

The TBARS levels expressed as malondialdehyde (MDA) were significantly \((P < 0.001)\) increased in the DLA control animals when compared to that of the normal control group. Treatment with MECP at 200 and 400 mg/kg body weight significantly \((P < 0.001)\) reduced the MDA levels when compared with the DLA control group.

**DISCUSSION**

The present study was aimed at analyzing the *in vitro* antitumor activity of various *Cissampelos pariera* extracts against the MCF-7 cancer cell line and *in vivo* antitumor activity of the active extract in DLA tumor-bearing mice. The MECP showed a significant \((P < 0.001)\) cytotoxic activity with an IC50 value of 95.5 μg/ml when compared with other extracts. The results of the *in vivo* study revealed that MECP with doses of 200 and 400 mg/kg body weight significantly \((P < 0.001)\) reduced the packed cell volume and tumor cell count, and restored the hematological and serum biochemical parameters to the normal values.

Ascetic fluid is the direct nutritional source for tumor cells, and therefore, a rapid increase in ascetic fluid with tumor growth would be a means to meet the nutritional requirement of tumor cells.\(^{[24,25]}\) An enormous increase in ascetic fluid volume was observed in the DLA tumor-bearing hosts, but the group treated with MECP showed a decrease in packed cell volume and viable tumor cell count, and an increased lifespan in the DLA tumor-bearing mice. The reliable measure for assessing the value of an anticancer drug was

---

**Table 3: Effect of MECP on the hematological parameters**

| Groups                  | Total WBC cells/ml x10^3 | RBC count mill/cumm | Hb gm/dl | Platelets lakhs/cumm |
|-------------------------|--------------------------|---------------------|----------|----------------------|
| Normal saline (5 mL/kg) | 10.78±0.28               | 4.55±0.39           | 12.52±0.57 | 3.45±0.43            |
| DLA control (1×10^6 cells/mouse) | 14.22±0.37**a          | 2.48±0.33**a       | 7.32±0.40**a | 1.79±0.25**a        |
| DLA+5F uracil (20 mg/kg) | 11.24±0.32**a           | 4.12±0.35**a       | 11.49±0.47**a | 2.89±0.31**a       |
| DLA+MECP (200 mg/kg)    | 12.69±0.44**a           | 3.38±0.22**b       | 10.29±0.34**a | 2.45±0.46**b       |
| DLA+MECP (400 mg/kg)    | 12.09±0.35**a           | 3.27±0.23**b       | 10.29±0.60**a | 2.60±0.40**b       |

Values are mean±SEM (n=12); *DLA control group versus normal saline group, **All treated groups versus DLA control group, *P<0.01, Data were assessed by one way ANOVA method followed by Tukey's multiple comparison, MECP: Methanol extract of *C. pariera*; DLA: Dalton's lymphoma ascites

**Table 4: Effect of MECP on serum biochemical parameters**

| Groups                  | Cholesterol (mg/dl) | TGL (mg/dl) | AST (U/L) | ALT (U/L) | ALP (U/L) |
|-------------------------|---------------------|-------------|-----------|-----------|-----------|
| Normal saline (5 mL/kg) | 116.8±1.81         | 135.18±3.36 | 43.09±1.41 | 35.55±1.74 | 128.99±1.42 |
| DLA control (1×10^6 cells/mouse) | 141.67±1.99**a     | 223.08±4.25**a | 86.7±1.59**a | 62.95±1.47**a | 242.84±2.72**a |
| DLA+5F uracil (20 mg/kg) | 120.96±2.05**a     | 170.04±2.82**a | 58.87±2.03**a | 44.39±2.42**a | 162.17±3.99**a |
| DLA+MECP (200 mg/kg)    | 123.41±5.01**a     | 184.09±4.70**a | 67.25±2.32**a | 51.60±1.23**a | 198.58±2.58**a |
| DLA+MECP (400 mg/kg)    | 124.50±2.31**a     | 179.09±3.20**a | 64.04±1.35**a | 47.61±2.75**a | 191.01±2.14**a |

\(^{(1×10^6 \text{ Cells/mouse})}\), Values are mean±SEM (n=12); *DLA control group versus normal saline group, **All treated groups versus DLA control group, *P<0.01, Data were assessed by one way ANOVA method followed by Tukey's multiple comparison, MECP: Methanol extract of *C. pariera*; DLA: Dalton's lymphoma ascites; TGL: Triglycerides; ALT: Alanine aminotransferase; AST: Aspartate amino transferase; ALP: Alkaline phosphatase

**Table 5: Effect of MECP on lipid peroxidation, SOD, and CAT in DLA bearing mice**

| Treatment                          | MDA (μM/g of protein) | SOD (IU/mg of protein) | CAT (IU/min/mg of protein) |
|------------------------------------|-----------------------|------------------------|----------------------------|
| Normal saline (5 mL/kg)            | 161±2.66              | 7.5±0.43               | 34.5±0.11                  |
| DLA control (1×10^6 cells/mouse)   | 500±5.91**a           | 3.8±0.36**a            | 9.5±0.25**a                |
| DLA+5-FU (20 mg/kg)                | 284±2.66**a           | 6.3±0.49**a            | 29±0.17**a                 |
| DLA+MECP (200 mg/kg)               | 313±8.7**a            | 6.9±0.29**a            | 19±2.42**a                 |
| DLA+MECP (400 mg/kg)               | 257±2.95**a           | 6.2±0.67**a            | 26±2.48**a                 |

Values are mean±SEM (n=6); *DLA control group versus normal saline group, **All treated groups versus DLA control group, *P<0.01, Data were assessed by One way Anova method followed by Tukey's multiple comparison, MECP: Methanol extract of *C. pariera*; DLA: Dalton's lymphoma ascites; TGL: Triglycerides; ALT: Alanine aminotransferase; AST: Aspartate amino transferase; ALP: Alkaline phosphatase; CAT: Catalase; FU: 5-Fluorouracil
increasing the lifespan of the tumor-bearing animal.\textsuperscript{[24]} It could, therefore, be understood that MECP increased the lifespan of DLA-bearing mice, which was due to the prevention of tumor development. Thus, it can be seen that MECP has antitumor activity against DLA-bearing mice at a dose of 200 mg/kg and 400 mg/kg body weight.

Myelosuppression and anemia are the major problems that are encountered in the treatment of cancer chemotherapy.\textsuperscript{[27,28]} Anemia occurring in tumor-bearing mice is mainly due to a reduction in erythrocytes or hemoglobin and this may happen either due to iron deficiency or due to hemolytic or myelopathic conditions.\textsuperscript{[29]} In the present study, the results indicate that MECP significantly increased the erythrocyte count and hemoglobin level when compared to those of the DLA control mice. Moreover, the WBC count had decreased when compared to that of the DLA control mice. These parameters showed that MECP showed a lesser toxic effect to the hemopoetic system and had a reasonably selective affinity to the tumor cell, and hence, it could maintain the normal hematological profile.

Increased levels of AST, ALT, ALP, and serum bilirubin are indicative of impaired liver functions due to cancer.\textsuperscript{[30,31]} The significantly increased levels of total AST, ALT, ALP, TGL, and cholesterol in the serum of tumor-inoculated animals indicated liver damage and loss of functional integrity of the cell membrane. Treatment with MECP at a dose of 200 and 400 mg/kg body weight restored the above-mentioned parameters to a normal level.

In the present study, the biochemical examination of DLA-inoculated animals showed marked changes indicating the toxic effect of the tumor. MECP significantly reduced the viability of tumor cells and packed cell volume, and normalized the hematological profile and serum biochemical parameters, raising the lifespan of the treated group as compared with those of the DLA control mice. Also the group treated with MECP improved the enzymatic and non-enzymatic antioxidant systems. Decrease of lipid peroxidation and augmentation of SOD and CAT in MECP-treated mice showed its potential as an inhibitor of DLA-induced intracellular oxidative stress. Thus, MECP demonstrated a remarkable in vitro and in vivo antitumor activity against DLA in mice, probably by attributing lipid peroxidation and increasing endogenous antioxidant systems.

**CONCLUSION**

The methanol extract of *Cissampelos pariera* contains high amounts of alkaloids, phenolic compounds, and flavonoids, and exhibits significant in vitro and in vivo antitumor activity. The antitumor activity may be due to its marked antioxidant potential.

**REFERENCES**

1. Mascarenhas M. Structure-activity characterization, a quick method to screen mushrooms for the presence of antitumor glucans. Mushroom Res 1994;3:77-80.
2. Nitha B, Meera CR, Janardhanan KK. Antitumor activity of ethanolic extract of *Lentinus dicholamellatus*. Amala Res Bull 2005;25:165-8.
3. Gupta M, Mazumder UK, Kumar RS, Kumar TS. Antitumor activity and antioxidant role of *Bauhinia racemosa* against Ehrlich ascites carcinoma in Swiss albino mice. Acta Pharmacol Sin 2004;25:1070-6.
4. Khare CP. Indian medicinal plants. New York: Springer; 2007. p. 162-3.
5. Singh BK, Pillai KK, Kohli K, Haque SE. Effect of *Cissampelos pareira* root extract on isoproterenol-induced cardiac dysfunction. J Nat Med 2013;67:51-60.
6. Surendran S, Eswaran MB, Vijayakumar M, Rao CV. In vitro and in vivo hepatoprotective activity of *Cissampelos pareira* against carbon-tetrachloride induced hepatic damage. Indian J Exp Biol 2011;49:939-45.
7. Bafna A, Mishra S. Antioxidant and immunomodulatory activity of the alkaloidal fraction of *Cissampelos pareira* linn. Sci Pharm 2010;78:21-31.
8. Ganguly M, Kr Borthakur M, Devi N, Mahanta R. Antifertility activity of the methanolic leaf extract of *Cissampelos pareira* infemale albino mice. J Ethnopharmacol 2007;111:688-91.
9. Amresh G, Reddy GD, Rao ChV, Singh PN. Evaluation of anti-inflammatory activity of *Cissampelos pareira* root in rats. J Ethnopharmacol 2007;110:526-31.
10. Amresh G, Singh PN, Rao ChV. Antinociceptive and antiarthritic activity of *Cissampelos pareira* roots. J Ethnopharmacol 2007;111:531-6.
11. Ramirez I, Carabot A, Melendez P, Carmona J, Jimenez M, Patel AV, et al. *Cissampeloflavone*, a chalcone-flavone dimer from *Cissampelos pareira*. Phytochemistry 2003;64:645-7.
12. Anwer F, Popli SP, Srivastava RM, Khare MP. Structures and solid state tautomeric forms of two novel antileukemic tropoloisoquinoline alkaloids, pareirubrines A and B, from *Cissampelos pareira*. Chem Pharm Bull (Tokyo) 1993;41:1418-22.
13. Basu DK. Studies on curariform activity of hayatinin methochloride, an alkaloid of *Cissampelos pareira*. Jpn J Pharmacol 1970;20:246-52.
14. Anwer F, Popli SP, Srivastava RM, Khare MP. Studies in medicinal plants. 3. Protobberine alkaloids from the roots of *Cissampelos pareira* Linn. Experientia 1968;24:999.
15. Kupchan SM, Patel AC, Fujita E. Tumor inhibitors. VI. Cissamparine, new cytotoxic alkaloid from *Cissampelos pareira*. Cytotoxicity of bisbenzylisoquinoline alkaloids. J Pharm Sci 1965;54:580-3.
16. Asirvatham R, Christina AJ. Anticancer activity of *Drosera indica* L., on Dalton’s lymphoma ascites (DLA) bearing mice. J Intercult Ethnopharmacol 2013;2:9-14.
17. Sreevidya N, Mehrota S. Spectrophotometric method for estimation of alkaloids precipitable with Dragendorff’s reagent in plant materials. J AOAC Int 2003;86:1124-7.
18. Chandler SF, Dodds JH. The Effect of phosphate, nitrogen and sucrose on the production of phenolics and solasidine in callus cultures of *Solanum lacinatum*. Plant Cell Rep 1983;2:205-8.
19. Arvouet-Grand A, Vennat B, Pourrat A, Legret P. Standardization of propolis extract and identification of principal constituents. J Pharm Belg 1994;49:462-8.

20. Gupta M, Mazumder UK, Haldar PK, Kandar CC. Anticancer activity of Indigofera aspalathoides and Wedelia calendulaceae in Swiss albino mice. Iran J Pharm Res 2007;6:141-5.

21. Ohkawa H, Onishi N, Yagi K. Assay for lipid peroxidation in animal tissue by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8.

22. Kakkar P, Das B, Vishwanath PN. A modified spectrophotometric assay of superoxide dismutase. Indian J Biochem Biophys 1984;21:130-2.

23. Aebi H. Catalase. In: Packer L, editor. Methods in Enzymatic Analysis. Vol. 2. New York: Academic Press; 1974. p. 673-84.

24. Prasad SB, Giri A. Antitumor effect of cisplatin against murine ascites Dalton’s lymphoma. Indian J Exp Biol 1994;32:155-62.

25. Haldar PK, Kar B, Bala A, Bhattacharya S, Mazumder UK. Antitumor activity of Sansevieria roxburghiana rhizome against Ehrlich ascites carcinoma in mice. Pharm Biol 2010;48:1337-43.

26. Clarkson D, Burchneal JH. Preliminary screening of antineoplastic drugs. Prog Clin Cancer 1965;1:625-9.

27. Prince VE, Greenfield RE. Anemia in cancer. In: Grenstein JP, Haddaw A, editors. Advances in Cancer Research. Vol. 5. New York: Academic Press; 1958. p. 199-200.

28. Hogland HC. Hematological complication of cancer chemotherapy. Semin Oncol 1982;9:95-102.

29. Fenninger LD, Mider GB. Energy and nitrogen metabolism in cancer. Adv cancer Res 1954;2:229-53.

30. Moss DW, Butterworth PJ. Enzymology and Medicine. London: Pitman Medical; 1974. p. 139.

31. Dortman RB, Lawhorn GT. Serum enzymes as indicators of chemical induced liver damage. Drug Chem Toxicol 1978;1:163-71.

Cite this article as: Thavamani BS, Mathew M, Dhanabal SP. Anticancer activity of Cissampelos pareira against Dalton’s lymphoma ascites bearing mice. Phcog Mag 2014;10:200-6.

Source of Support: Nil, Conflict of Interest: None declared.